CARGO Therapeutics reports Q1 2024 net loss $35.8M; Phase 2 firi-cel trial on track for 1H25 interim data

CARGO Therapeutics, Inc.

2024-Q1 EPS reported -$0.87

Q1 2024 net loss of $35.8M ($0.87/share); cash, equivalents and marketable securities $375.9M providing runway into 2026.
Phase 2 FIRCE-1: 26 sites activated, >20 patients dosed; IDMC recommended continuation without modifications; interim results expected 1H25.
Phase 1 Stanford firi-cel data: median OS 25.7 months at DL1; ORR 68%, CR 53% across all patients (n=38) at median follow-up 31.4 months.
Dr. Kapil Dhingra appointed to board of directors in April 2024.
R&D expenses $30.5M (incl. $1.7M stock-based comp); G&A expenses $10.3M (incl. $2.2M stock-based comp).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

CARGO Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, CARGO Therapeutics, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.